Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Jefferies

Advanced Heart Failure and Transplant Cardiology Memphis, TN Medical Doctor

NPI 1619920469 CMS profile 694246

1211 Union Ave Ste 965, Memphis, TN 38104

Open in the dashboard

General payments

$719,612

549 records reported · program years 2019–2025

Research payments

$6,896

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$725,809 paid to institutions, not to them · program years 2019–2024

Through program year 2025, John Jefferies of Memphis, TN is reported in the CMS Open Payments database as having received $719,612 across 549 general payments and $6,896 in research payments paid to them. Separately, studies naming them as principal investigator received $725,809 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55,385 35
2024 General $62,970 40
2023 General $254,821 130
2023 Research $3,200 1
2022 General $92,078 110
2022 Research $18 1
2021 General $117,776 71
2021 Research $1,813 2
2020 General $89,542 80
2019 General $47,042 83
2019 Research $1,865 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Jefferies
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to John Jefferies were reported at $55,385. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year John Jefferies Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $47,042 $863 $224–$4,562 $163
2020 $89,542 $452 $122–$3,992 $114
2021 $117,776 $550 $159–$3,571 $132
2022 $92,078 $729 $221–$4,357 $149
2023 $254,821 $1,002 $309–$5,827 $160
2024 $62,970 $931 $273–$5,204 $164
2025 $55,385 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CHF Solutions, Inc $359,973 75 payments
  2. Genzyme Corporation $137,784 91 payments
  3. E.R. Squibb & Sons, L.L.C. $61,552 48 payments
  4. Amicus Therapeutics, Inc. $39,054 38 payments
  5. NS Pharma, Inc. $31,610 45 payments
  6. Daxor Corporation $18,103 29 payments
  7. Pfizer Inc. $16,136 15 payments
  8. Medtronic, Inc. $15,186 66 payments
  9. Chiesi USA, Inc. $13,706 9 payments
  10. Abbott Laboratories $6,188 45 payments
  11. Other $20,320 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $302,088 69 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $228,037 72 payments
  3. Honoraria $103,885 36 payments
  4. Travel and Lodging $49,191 114 payments
  5. Food and Beverage $33,797 252 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,575 4 payments
  7. Education $39 2 payments
Products named General payments · program years 2019–2025
  1. AQUADEX SMARTFLOW CONSOLE $326,296 59 payments
  2. FABRAZYME Genetic Disease $53,344 29 payments
  3. CAMZYOS $34,279 24 payments
  4. Aquadex $33,677 16 payments
  5. VILTEPSO $31,160 44 payments
  6. GALAFOLD $27,975 23 payments
  7. FABRAZYME Rare Disease Genetics $21,394 23 payments
  8. BVA-100 $18,103 29 payments
  9. VYNDAQEL $12,520 10 payments
  10. NO PRODUCT DISCUSSED $7,864 7 payments
  11. Other $34,568 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $3,200 1 payment
  2. Genzyme Corporation $1,865 11 payments
  3. Eli Lilly and Company $1,138 2 payments
  4. Medtronic, Inc. $693 1 payment

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record